Communiqués Zai Lab Limited Hong Kong S.E.

Actions

9688

KYG9887T1168

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:21 12/06/2026			Varia. 5j.	Varia. 1 janv.
13,18 ^HKD	-1,27%		+4,60%	-3,44%

10/06	Les actions asiatiques cotées aux États-Unis sous forme d'ADR s'inscrivent en baisse lors de la séance de mercredi	MT
09/06	La Chine approuve le Tivdak de Pfizer dans le cancer du col de l'utérus

Communiqués

09/06	Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer	BU
22/05	Zai Lab Announces Changes to Senior Leadership Team	BU
11/05	Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)	BU
07/05	Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates	BU
22/04	Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026	BU
20/04	Zai Lab : AACR IR Presentation vFINAL	PU
18/04	Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases	BU
17/04	Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas	BU
01/04	Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy	BU
17/03	Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)	BU
26/02	Zai Lab : ZLAB 4Q25 Corporate Presentation EN vf	PU
26/02	Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates	BU
10/02	Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026	BU
13/01	Zai Lab : JPM 2026 Presentation vFinal	PU
13/01	Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference	BU
06/01	Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors	BU
05/01	Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference	BU
23/12	Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia	BU
08/12	Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis	BU
07/12	Zai Lab Announces Updates to China’s National Reimbursement Drug List	BU
10/11	Zai Lab : Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week	PU
06/11	Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates	BU
31/10/25	Zai Lab Announces Participation in Investor Conferences in November and December 2025	BU
24/10/25	Zai Lab : Zocilurtatug pelitecan (ZL 1310) AACR NCI EORTC 2025 Highlights	PU
24/10/25	Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study	BU